SEC Stock Data Quick Answer XERIANT, INC. reported Cash and Equivalents of $962.5 thousand for fiscal year 2021. XERIANT, INC. Cash and Equivalents — Annual History Fiscal Year Cash and Equivalents YoY Change 2021 $962.5K +2374.8% 2020 $38.9K +1184.0% 2019 $3.0K — 2018 $0.00 -100.0% 2017 $4.5K -59.4% 2016 $11.1K -97.0% 2015 $362.7K +986.9% 2014 $33.4K +200.5% 2013 … Read more
Quick Answer XERIANT, INC. reported Total Assets of $68.2 thousand for fiscal year 2025. XERIANT, INC. Total Assets — Annual History Fiscal Year Total Assets YoY Change 2025 $68.2K -90.4% 2024 $713.0K +326.6% 2023 $167.1K -86.8% 2022 $1.27M +10.8% 2021 $1.15M +342.5% 2020 $258.9K +8447.3% 2019 $3.0K -87.3% 2018 $23.9K -21.6% 2017 $30.5K -81.8% 2016 … Read more
Quick Answer XERIANT, INC. reported Diluted EPS of $0.00 per share for fiscal year 2025. XERIANT, INC. Diluted EPS — Annual History Fiscal Year Diluted EPS YoY Change 2025 $0.00 +100.0% 2024 -$0.01 +0.0% 2018 -$0.01 +50.0% 2017 -$0.02 +0.0% 2016 -$0.02 +60.0% 2015 -$0.05 -66.7% 2014 -$0.03 -3100.0% 2013 $0.00 — Quarterly Diluted EPS … Read more
Quick Answer XERIANT, INC. reported Net Income of -$1.65 million for fiscal year 2025. XERIANT, INC. Net Income — Annual History Fiscal Year Net Income YoY Change 2025 -$1.65M +46.9% 2024 -$3.10M +56.3% 2023 -$7.10M +46.6% 2022 -$13.30M -392.2% 2021 -$2.70M -286.3% 2020 -$699.6K -725.4% 2019 -$84.8K +89.9% 2018 -$838.4K +21.4% 2017 -$1.07M +4.4% 2016 … Read more
Quick Answer XERIANT, INC. reported Total Revenue of $79.7 thousand for fiscal year 2018. XERIANT, INC. Total Revenue — Annual History Fiscal Year Total Revenue YoY Change 2018 $79.7K -87.4% 2017 $630.0K -72.4% 2016 $2.29M -17.1% 2015 $2.76M +21.7% 2014 $2.26M +31.3% 2013 $1.72M — Quarterly Total Revenue Quarter Ending Total Revenue YoY QoQ March … Read more
Quick Answer XERIANT, INC. reported Total Revenue of $79.7 thousand for fiscal year 2018. XERIANT, INC. — Key Financials by Year Metric 2025 2024 2023 2022 2021 2020 Total Revenue — — — — — — Net Income -$1.65M+46.9% -$3.10M+56.3% -$7.10M+46.6% -$13.30M-392.2% -$2.70M-286.3% -$699.6K-725.4% Diluted EPS $0.00+100.0% -$0.01 — — — — Total Assets $68.2K-90.4% … Read more
Quick Answer Xenon Pharmaceuticals Inc. reported Shares Outstanding of 80.01 million shares for fiscal year 2025. Xenon Pharmaceuticals Inc. Shares Outstanding — Annual History Fiscal Year Shares Outstanding YoY Change 2025 80.01M +4.7% 2024 76.42M +1.4% 2023 75.37M +20.4% 2022 62.59M +21.2% 2021 51.63M +47.5% 2020 35.01M +24.4% 2019 28.14M +9.3% 2018 25.75M +43.1% 2017 … Read more
Quick Answer Xenon Pharmaceuticals Inc. reported Operating Income of -$373.07 million for fiscal year 2025. Xenon Pharmaceuticals Inc. Operating Income — Annual History Fiscal Year Operating Income YoY Change 2025 -$373.07M -33.6% 2024 -$279.30M -30.5% 2023 -$214.05M -65.7% 2022 -$129.14M -63.5% 2021 -$78.99M -152.4% 2020 -$31.30M +26.9% 2019 -$42.82M -12.6% 2018 -$38.04M -16.8% 2017 -$32.58M … Read more
Quick Answer Xenon Pharmaceuticals Inc. reported R&D Expense of $300.94 million for fiscal year 2025. Xenon Pharmaceuticals Inc. R&D Expense — Annual History Fiscal Year R&D Expense YoY Change 2025 $300.94M +43.0% 2024 $210.39M +25.6% 2023 $167.51M +58.4% 2022 $105.77M +40.2% 2021 $75.46M +49.4% 2020 $50.52M +30.1% 2019 $38.84M +64.4% 2018 $23.63M -7.6% 2017 $25.57M … Read more
Quick Answer Xenon Pharmaceuticals Inc. reported Stockholders Equity of $581.76 million for fiscal year 2025. Xenon Pharmaceuticals Inc. Stockholders Equity — Annual History Fiscal Year Stockholders Equity YoY Change 2025 $581.76M -22.9% 2024 $754.90M -18.6% 2023 $927.92M +28.6% 2022 $721.50M +31.2% 2021 $550.03M +221.0% 2020 $171.35M +86.3% 2019 $91.98M -11.0% 2018 $103.30M +187.5% 2017 $35.93M … Read more